Atyr PHARMA INC (NASDAQ:ATYR – Free Report) – Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Atyr PHARMA in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will earn ($0.78) per share for the year. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.91) per share.
Atyr PHARMA (NASDAQ:ATYR – Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02.
View Our Latest Research Report on ATYR
Atyr PHARMA Trading Down 2.0%
Shares of ATYR stock opened at $5.39 on Wednesday. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $5.98. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $3.65 and its two-hundred day moving average is $3.57. The company has a market cap of $479.73 million, a PE ratio of -5.73 and a beta of 0.88.
Institutional Investors Weigh In On Atyr PHARMA
Several hedge funds and other institutional investors have recently modified their holdings of ATYR. D.A. Davidson & CO. acquired a new stake in shares of Atyr PHARMA in the fourth quarter worth $141,000. Charles Schwab Investment Management Inc. bought a new position in Atyr PHARMA in the fourth quarter worth $144,000. Victory Capital Management Inc. bought a new position in Atyr PHARMA in the fourth quarter worth $37,000. Raymond James Financial Inc. bought a new position in Atyr PHARMA in the fourth quarter worth $39,000. Finally, Farther Finance Advisors LLC bought a new position in Atyr PHARMA in the fourth quarter worth $88,000. Institutional investors and hedge funds own 61.72% of the company’s stock.
About Atyr PHARMA
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Recommended Stories
- Five stocks we like better than Atyr PHARMA
- What to Know About Investing in Penny Stocks
- Is Consumer Discretionary a Dead End? These 3 Stocks Say No
- Large Cap Stock Definition and How to Invest
- Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile
- Stock Market Sectors: What Are They and How Many Are There?
- Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive?
Receive News & Ratings for Atyr PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.